Sanofi and GlaxoSmithKline’s next generation Covid-19 vaccine could be used as a booster, after new data suggested that it elicits a strong immune response against the Omicron variant.
The French healthcare company said the “next-generation” booster jab delivered a “strong immune response” against variants of Covid-19, including Omicron, after two trials. It was safe and well tolerated in the study of 247 people.
The vaccine makers said their jab increased antibodies to tackle the BA.1 Omicron strain by 40-fold in participants who had received two messengerRNA shots, the technology used in popular vaccines from Moderna and BioNTech/Pfizer.
您已閱讀25%（648字），剩餘75%（1904字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。